Netherland-based injectable drug delivery products producer InnoCore Pharmaceuticals has signed an exclusive license and collaboration agreement with Allergan (AGN), to develop new medicines for ophthalmic diseases.
The deal will see the companies expand their existing collaboration and jointly develop long-acting ocular drug delivery products for the treatment of ophthalmic diseases.
Under the deal, InnoCore will use its patented SynBiosys polymeric drug delivery platform to formulate Allergan’s proprietary drugs into pharmaceutical products that would be capable of sustained release for many months following a single ocular injection.
InnoCore’s SynBiosys drug delivery platform is based on new biodegradable multi-block co-polymers with different molecular architectures, which enable precise and site-specific delivery of drugs for predetermined periods of time, ranging from weeks to many months.
InnoCore uses its SynBiosys polymer platform to develop biodegradable sustained release depots for precisely controlled delivery of therapeutic compounds.
US-based multi-speciality health care firm Allergan is specialised in the development of controlled release ophthalmology medicines.
